Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $387.16M
Last updated: Nov 17, 2026 at 11:05 AM ET
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Competitors
The companies most similar to Contineum Therapeutics, Inc. Class A Common Stock are Prelude Therapeutics (PRLD), Entera Bio (ENTX) and Prothena Corporation (PRTA). By market cap, Contineum Therapeutics, Inc. Class A Common Stock ranks 7th of the 13 companies on this page; Entera Bio (ENTX) is the largest at $541.57M.
Peer Comparison
CTNM's revenue growth of 0.0% is above the peer median of -54.4%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | $387.16M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Prelude Therapeutics Inc (PRLD) | $275.32M | N/A | 16.3x | -269.7% | N/A | 41.0% | 0.00% |
| Entera Bio Ltd (ENTX) | $541.57M | N/A | N/A | 0.0% | -8.5% | -100.0% | 0.00% |
| Prothena Corporation plc (PRTA) | $419.01M | N/A | 7.8x | -45.4% | N/A | -74.3% | 0.00% |
| Lineage Cell Therapeutics Inc (LCTX) | $231.35M | N/A | 18.7x | 16.2% | -6.7% | -61.0% | 0.00% |
| CorMedix Inc (CRMD) | $370.64M | 6.3x | 0.9x | 15.5% | 13.9% | -47.7% | 0.00% |
| CytomX Therapeutics Inc (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| Tectonic Therapeutic, Inc. (TECX) | $413.27M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Century Therapeutics Inc (IPSC) | $299.63M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Candel Therapeutics Inc (CADL) | $486.37M | N/A | N/A | 0.0% | -43.5% | 0.0% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Fulcrum Therapeutics Inc (FULC) | $287.96M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Rezolute Inc (RZLT) | $353.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $388.62M | 6.3x | 16.3x | 0.0% | -7.6% | -54.4% | 0.00% |
Similar Companies
These are the 12 companies most similar to Contineum Therapeutics, Inc. Class A Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Prelude Therapeutics Inc (PRLD) | Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized... | PRLD competitors |
| Entera Bio Ltd (ENTX) | Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies... | ENTX competitors |
| Prothena Corporation plc (PRTA) | Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases... | PRTA competitors |
| Lineage Cell Therapeutics Inc (LCTX) | Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment... | LCTX competitors |
| CorMedix Inc (CRMD) | CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious... | CRMD competitors |
| CytomX Therapeutics Inc (CTMX) | CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. | CTMX competitors |
| Tectonic Therapeutic, Inc. (TECX) | Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel... | TECX competitors |
| Century Therapeutics Inc (IPSC) | Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy... | IPSC competitors |
| Candel Therapeutics Inc (CADL) | Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform... | CADL competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
| Fulcrum Therapeutics Inc (FULC) | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined... | FULC competitors |
| Rezolute Inc (RZLT) | Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. | RZLT competitors |
Frequently Asked Questions About CTNM
Who are Contineum Therapeutics, Inc. Class A Common Stock's main competitors?
The companies most similar to Contineum Therapeutics, Inc. Class A Common Stock include Prelude Therapeutics (PRLD), Entera Bio (ENTX), Prothena Corporation (PRTA), Lineage Cell Therapeutics (LCTX) and CorMedix (CRMD), listed from the closest match.
Who is Contineum Therapeutics, Inc. Class A Common Stock's biggest competitor?
Entera Bio (ENTX) is the largest of the similar companies at $541.57M; Prelude Therapeutics (PRLD) is the closest match by business profile, size, sector and industry.
How does CTNM stock compare with its competitors?
CTNM's net margin is 0.0% against a peer median of 0.0%.
Which of Contineum Therapeutics, Inc. Class A Common Stock's competitors pays a higher dividend?
Contineum Therapeutics, Inc. Class A Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Contineum Therapeutics, Inc. Class A Common Stock bigger than its competitors?
No. Contineum Therapeutics, Inc. Class A Common Stock is 7th by market cap among the 13 companies on this page; the largest is Entera Bio (ENTX) at $541.57M.
CTNM pages: Overview, Earnings, Forecast, Financials, Competitors